Antabio SAS

MEM-ANT3310, which Antabio is developing to address antimicrobial resistance (AMR) in severe hospital infections, is among the latest products to secure a place on PRIME, the European Medicines Agency

The end of 2023 is proving no different from the end of any other year, with venture capital firms and biopharmaceutical companies closing out a flurry of new VC funds and financings before December d

Oncology research and development has consistently seen significant growth around the world in the past few years, but trial diversity, and especially inclusion of Black and Hispanic patients, has con

The lack of a viable commercial route for bringing innovative antibacterial treatments to market leaves France-based Antabio SAS little option other than to seek a partner or acquirer after early-st